EFTR Novinky na Forexu
EFFECTOR Reports Results Of Phase2 KICKSTART Trial Of Tomivosertib-Pembrolizumab In NSCLC
eFFECTOR Therapeutics, Inc. (EFTR) announced Thursday topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 =50%.
RTTNews
|
Před 285 dny
EFFECTOR Says First Patient Dosed In Second Cohort Of Phase 1b Trial Of Zotatifin For COVID-19
Biopharmaceutical company eFFECTOR Therapeutics, Inc. (EFTR) announced Wednesday it has dosed the first patient in the second cohort of its Phase 1b clinical trial of zotatifin in non-hospitalized adults with confirmed COVID-19 infection.
RTTNews
|
Před 853 dny
